FDA Updates Safety Communication on Compounded GLP-1 Drugs for Weight Loss
The FDA updated its safety communication highlighting concerns about unapproved compounded GLP-1 drugs used for weight loss, citing over 1,100 adverse event reports.
Key Takeaways
- FDA received 1,100+ adverse event reports for compounded GLP-1s through July 2025
- Adverse event reports do not establish that compounding caused the events
- Some reports may reflect expected GLP-1 side effects, not compounding issues
- Patients should report adverse events to FDA MedWatch
Background
The FDA updated its concerns page for compounded GLP-1 drugs used for weight loss, citing more than 1,100 adverse event reports associated with compounded versions of semaglutide and tirzepatide received through July 2025.
Context
Adverse event reports to the FDA do not establish causation. The FDA notes that some of these reports may involve expected side effects of GLP-1 medications (such as nausea) rather than issues specific to compounding. However, the volume of reports warrants consumer awareness.
Recommendations
The FDA recommends that patients using compounded GLP-1 medications report any adverse events to the FDA MedWatch program and discuss concerns with their healthcare provider. Patients should verify that their compounding pharmacy is properly registered and licensed.
Source: View original on FDA.gov
Disclaimer: This article summarizes publicly available FDA data for informational purposes only. It is not medical or legal advice. Always consult your healthcare provider and verify with official FDA sources before making decisions about your treatment.
Related Safety Guides
GLP-1 Safety Alerts
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.